SCHEMBL5993541

SCHEMBL5993541

CC(=O)Oc1cc(F)c(C(C)(C)C(F)(F)F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.42
CYP4A11 Q02928 2/20 0.42
CYP3A4 P08684 2/20 0.40
LMNA P02545 4/20 0.37
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 1/20 0.37
TTR P02766 1/20 0.37
TP53 P04637 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
BACE1 P56817 3/20 0.36
CYP19A1 P11511 1/20 0.34
ACHE P22303 2/20 0.33
HSD17B10 Q99714 2/20 0.33
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21718929 0.84 CYP4F2 (0.46) CYP4F2CYP4A11CYP3A4LMNAKDM4E
SCHEMBL17356422 0.84 CYP4F2 (0.46) CYP4F2CYP4A11CYP3A4LMNAKDM4E
SCHEMBL1474395 0.76 TAAR1 (0.42) CYP3A4ALDH1A1
SCHEMBL3825842 0.76 SMN1; SMN2 (0.45) LMNASMN1; SMN2HSD17B10PKMHPGD
SCHEMBL823692 0.75 CYP4F2 (0.52) CYP4F2CYP4A11CYP3A4LMNAKDM4E
SCHEMBL17355735 0.74 CYP4F2 (0.50) CYP4F2CYP4A11CYP3A4LMNAKDM4E
SCHEMBL16322544 0.74 CYP4F2 (0.50) CYP4F2CYP4A11CYP3A4LMNAKDM4E
SCHEMBL1473406 0.72 HTR1D (0.33)
SCHEMBL10680953 0.72 CYP3A4 (0.47) CYP3A4LMNAKDM4EMAPTMEN1
SCHEMBL1473762 0.71 GABRA1 (0.36) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060205980-A1 Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists PFIZER, INC. 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205980-A1 Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists CNR1, HVCN1, AVPR1A CYP4F2 1973/4885CYP4A11 1625/4885CYP3A4 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.